Lenvima to get benefit as first-line treatment of hepatocellular carcinoma

16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...

Read more →

Pharmacists demand audit over Gliatilin’s insurance benefit

27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...

Read more →

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anaemia

 1 August 2019 - Novartis Korea’s Revolade (eltrombopag olamine) will receive reimbursement for treating people with severe aplastic anaemia who ...

Read more →

Takeda’s Zejula poised to change local ovarian cancer treatment market

29 July 2019 - Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance benefit, according to the Health Insurance Review and ...

Read more →

Pfizer's Besponsa, Takeda's Zejula likely to get insurance coverage

26 July 2019 - Pfizer's Besponsa, a B-cell lymphoblastic leukaemia treatment, and Takeda's Zejula, an ovarian cancer treatment, have passed ...

Read more →

Two cancer immunotherapy makers face different situations in reimbursement talks

18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...

Read more →

Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz

1 July 2019 - The Korean branch of Eli Lilly said that it had gained additional reimbursement for its psoriasis ...

Read more →

Delayed patient access to innovative medical technologies in South Korea: a lead-time analysis of reimbursement coverage determinations

20 June 2019 - Timely access to innovative medical technologies driven by accelerated patient access pathways can substantially improve the health ...

Read more →

Role of health technology assessment in drug policies: Korea

13 June 2019 - South Korea is the first Asian country to mandate the submission of pharmacoeconomic data for reimbursement decision ...

Read more →

Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific Region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea

13 June 2019 - Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of ...

Read more →

Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug

12 June 2019 - Korean patients with severe atopic dermatitis gathered in front of the National Assembly on Tuesday to ...

Read more →

HIV prevention pill to get insurance benefit in Korea

30 May 2019 - The local medical community is likely to use a drug to prevent HIV infection in earnest.  ...

Read more →

Roche’s breast cancer drug gains more insurance benefits

21 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Roche’s breast cancer therapy Perjeta (pertuzumab) ...

Read more →

Korean Government to reduce biopharmaceutical approval period to half

20 May 2019 - The Korean government plans to reduce by half the current one and a half years of ...

Read more →

Celgene’s myelodysplastic syndrome treatment gets more insurance benefits

7 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Celgene’s multiple myeloma drug, Revlimid (ingredient: ...

Read more →